The antipsychotic drug brexpiprazole (Rexulti) failed in two phase III studies for treating manic episodes in bipolar I disorder, Lundbeck and Otsuka Pharmaceutical announced.
However, a recent meta-analysis found the breast cancer drug tamoxifen showed a benefit for treating bipolar episodes of mania. The benefits were seen with monotherapy or when added to lithium or valproate. (Journal of Psychopharmacology)
Women whose male partners regularly watched porn were more likely to experience symptoms of an eating disorder. “We often talk about the influences of media, family and friends on eating disorders, but little has been done to determine how a partner’s influence might contribute to a woman’s disordered eating,” said author Tracy Tylka, PhD, of The Ohio State University in Columbus, in a statement. (International Journal of Eating Disorders)
In related news, both cognitive behavioral therapy (CBT) tailored for body dysmorphic disorder as well as supportive psychotherapy appeared to improve symptoms of body dysmorphic disorder, although CBT was tied to more consistent symptom improvements. (JAMA Psychiatry)
The FDA issued a warning against plasma infusions from young blood donors claiming to treat conditions like dementia, Alzheimer’s, and post-traumatic stress disorder (PTSD).
The cannabinoid Sativex, which is approved for multiple sclerosis–related spasticity outside the U.S., will be tested as a possible treatment for dementia-related agitation in a phase II clinical trial in the U.K.
Adjunctive treatment with an antidepressant was tied to a lowered risk for hospitalization in people with schizophrenia. On the other hand, adjunctive therapy with benzodiazepines was tied to a higher risk of psychiatric hospitalization. (JAMA Psychiatry)
Recruitment is underway for the phase III trial of troriluzole for generalized anxiety disorder, Biohaven Pharmaceutical announced.
Source: MedicalNewsToday.com
